Solving the PFAS Challenge Starts with a Different Question

For years, the PFAS conversation centered on detection.

Organizations wanted to know whether per- and polyfluoroalkyl substances (PFAS) were present, where they were occurring and what emerging regulations might mean for their operations. Today, the focus is shifting from identification to accountability.

Across utilities, industrial facilities, landfills and infrastructure assets, organizations are facing lower regulatory limits, increasing public scrutiny and growing pressure to justify treatment decisions. The U.S. Environmental Protection Agency’s drinking water standards, including limits of 4.0 parts per trillion for both perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic acid (PFOS), have accelerated that shift.

Many organizations still approach PFAS treatment as a technology selection exercise. Yet treatment success is increasingly determined by something broader: understanding site-specific chemistry, validating performance before implementation and managing risk throughout the treatment lifecycle.

The organizations making the strongest decisions today are not necessarily those adopting the newest technology. They are the ones building confidence in the outcomes they need to achieve.

One of the lessons emerging across the industry is that there is no universal PFAS solution.

Most operators recognize that PFAS rarely exists in isolation. Co-contaminants, fluctuating influent chemistry, operational constraints and residuals management requirements all influence treatment performance. What works effectively at one site may not achieve the same results at another.

This becomes even more important as organizations encounter increasingly complex waste streams, including landfill leachate, industrial process water and waters containing short-chain and ultra-short-chain PFAS compounds. These challenges require treatment approaches built around the specific chemistry of the site rather than assumptions about what has worked elsewhere.

That is driving greater interest in integrated treatment strategies that combine technologies such as ion exchange resins, foam fractionation, membranes and polishing systems. Platforms such as SORBIX™ PURE, SORBIX™ RePURE and FOAM-X™ reflect this shift toward treatment solutions designed around specific water conditions and operational requirements.

Organizations that invest in understanding water chemistry and validating treatment options before committing capital are consistently better positioned to achieve reliable long-term outcomes. Testing and characterization are not simply technical exercises. They are risk management tools that support better decisions.

As treatment expectations rise, evidence is becoming more important than promises.

Bench-scale studies, Rapid Small Scale Column Testing, pilot programs and field validation help organizations understand how treatment technologies are likely to perform before they are deployed at full scale. This provides a stronger foundation for investment decisions and reduces uncertainty around long-term performance.

The value of this approach becomes clear when treatment performance must be demonstrated to regulators, communities and internal stakeholders. Removal efficiencies achieved in controlled environments are important, but operational confidence comes from understanding how systems perform under the conditions they will actually face.

A recent industrial PFAS treatment pilot treated more than 43,000 gallons of PFAS-impacted water and achieved greater than 99.8 percent PFOS removal by mass, with effluent concentrations below discharge requirements. Results like these matter because they demonstrate more than removal efficiency. They show how testing, treatment selection and operational planning can come together to support real-world decisions.

The PFAS treatment market continues to evolve rapidly. New materials, treatment approaches and destruction technologies are entering the market every year.

That innovation is important, but technology alone is rarely the deciding factor. The organizations achieving the strongest outcomes are those that evaluate innovations through the lens of operational performance, lifecycle costs, residuals management and long-term reliability.

Recent advances in regenerable ion exchange, foam fractionation and PFAS concentration technologies are helping address challenges that conventional treatment approaches can struggle to solve. Across the sector, there is growing recognition that successful PFAS management requires science, engineering and operations to work together.

Innovation creates opportunities, but field validation ultimately determines value. The most effective treatment strategies are those that can move confidently from the laboratory to pilot testing and ultimately into full-scale operation without losing sight of operational realities.

Regulators are demanding stronger evidence. Communities expect greater transparency. Asset owners need treatment decisions that remain defensible as standards continue to evolve.

Organizations that focus solely on technology selection risk missing the larger challenge. The opportunity lies in building treatment strategies that can withstand future scrutiny while balancing performance, operational realities and long-term risk.

The PFAS challenge has changed. Success is no longer measured by whether contaminants can be detected. It is measured by whether treatment performance can be demonstrated with confidence.